The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | ESMO GI 2026 pancreatic cancer highlights: KRAS inhibitors, TRIPP-FFX, and PROCEADE-PanTumor
Teresa Macarulla, MD, Vall d’Hebron University Hospital, Barcelona, Spain, discusses highlights in pancreatic cancer presented at the ESMO GI 2026 Meeting. Dr Macarulla explores KRAS inhibitors, the Phase II TRIPP-FFX trial (NCT05466799) of targeted intratumoral brachytherapy using beta radiation-emitting phosphorus-32 (P-32) microparticles with FOLFIRINOX chemotherapy and the Phase Ib/II PROCEADE-PanTumor study (NCT06710132) of the anti-CEACAM5 antibody-drug conjugate (ADC) precemtabart tocentecan. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
